Successfully launching orphan medicines will become even more important over the next five years as more patients with rare diseases have treatments available and the growing number of disease registries, increases public and policy maker awareness.

Join our webinar on Thursday 13th June from 15:00-16:00 BST and look at how pharmaceutical companies can optimise all the activities needed to take orphan medicines from clinical development to commercialisation, including:

• The three fundamental orphan medicine launch excellence challenges
• The ways in which companies launching orphan medicines can learn from excellence in mainstream launches
• The specific areas of focus that are crucial for orphan medicines launch excellence

Speakers

• Angela McFarlane, Market Development Director, IQVIA
• Sarah Rickwood, Vice President, European Thought Leadership, IQVIA
• Peter Meeus, European Orphan Medicines Commercial Excellence Executive
• Paul Tunnah, CEO, pharmaphorum (moderator)